Policy & Regulation
iLoF collaborates with Bluepharma to deploy AI-powered Optomics
5 March 2026 - Digital health company iLoF, developer of Optomics, an AI-powered photonics platform for developing personalised solutions for drug development and clinical research, announced on Wedne...
Akeso agrees clinical trial collaboration with INOVIO
5 March 2026 - Chinese biopharmaceutical company Akeso Inc (HK:9926) announced on Wednesday that it has agreed a clinical trial collaboration and supply agreement with INOVIO (NASDAQ:INO), a US-based ...
Airiver Medical's Airiver Pulmonary DCB receives US FDA Breakthrough Device Designation
5 March 2026 - Airiver Medical, a clinical stage company developing technologies to help patients who suffer from certain respiratory tract conditions, announced on Wednesday that it has received Brea...
Frontage Laboratories acquires Teddy Clinical Research Laboratory in China
5 March 2026 - US-based global CRO/CDMO Frontage Laboratories Inc, a subsidiary of Frontage Holdings Corporation (HKEX:1521), announced on Wednesday that it has acquired Teddy Clinical Research Labora...
Allergy Therapeutics reports positive biomarker data from PROTECT trial
4 March 2026 - Biotechnology company Allergy Therapeutics plc (AIM: AGY) on Wednesday reported positive biomarker results from its Phase I/IIa PROTECT trial of VLP Peanut, following the achievement of...
HUTCHMED doses first patient in global trial of ATTC candidate HMPL-A580
4 March 2026 - Biopharmaceutical company HUTCHMED (China) Limited (Nasdaq: HCM) (AIM: HCM) (HKEX: 13) announced on Wednesday that it has initiated a global Phase I/IIa clinical trial of its antibody-t...